Control of viral infectivity by tripartite motif proteins

Human Gene Therapy

Volumn 16, Issue 10, 2005, Pages 1125-1132

  Towers, Greg J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; NUCLEIC ACID; PROTEIN; TRIPARTITE MOTIF PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; NONHUMAN; PRIMATE; PROTEIN ANALYSIS; PROTEIN MOTIF; RETROVIRUS; REVIEW; SPECIES DIFFERENCE; VIRUS CAPSID; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; CARRIER PROTEINS; CYTOPLASMIC GRANULES; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; GENE THERAPY; HUMANS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; SPECIES SPECIFICITY; VIRUS REPLICATION;

MAMMALIA;

EID: 26644435983     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1125     Document Type: Review

References (78)

1. ALIN, K., and GOFF, S.P. (1996). Amino acid substitutions in the CA protein of Moloney murine leukemia viras that block early events in infection. Virology 222, 339-351.
2. APETREI, C., KAUR, A., LERCHE, N.W., METZGER, M., PANDREA, I., HARDCASTLE, J., FALKENSTEIN, S., BOHM, R., KOEHLER, J., TRAINA-DORGE, V., WILLIAMS, T., STAPRANS, S., PLAUCHE, G., VEAZEY, R.S., MCCLURE, H., LACKNER, A.A., GORMUS, B., ROBERTSON, D.L., and MARX, P.A. (2005). Molecular epidemiology of simian immunodeficiency viras SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J. Virol. 79, 8991-9005.
3. BESNIER, C., TAKEUCHI, Y., and TOWERS, G. (2002). Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U.S.A. 99, 11920-11925.
4. BESNIER, C., YLINEN, L., STRANGE, B., LISTER, A., TAKEUCHI, Y., GOFF, S.P., and TOWERS, G.J. (2003). Characterization of murine leukemia virus restriction in mammals. J. Virol. 77, 13403-13406.
5. BIENIASZ, P.D. (2004). Intrinsic immunity: A front-line defense against viral attack. Nat. Immunol. 5, 1109-1115.
6. BOCK, M., BISHOP, K., TOWERS, G., and STOYE, J.P. (2000). Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol. 74, 7422-7430.
7. BOONE, L.R., INNES, C.L., and HEITMAN, C.K. (1990). Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J. Virol. 64, 3376-3381.
8. BORDEN, K.L. (2002). Pondering the promyelocytic leukemia protein (PML) puzzle: Possible functions for PML nuclear bodies. Mol. Cell. Biol. 22, 5259-5269.
9. CAIRNS, T.M., and CRAVEN, R.C. (2001). Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. J. Virol. 75, 242-250.
10. CHEE, A.V., LOPEZ, P., PANDOLFI, P.P., and ROIZMAN, B. (2003). Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol. 77, 7101-7105.
11. CHELBI-ALIX, M.K., and DE THE, H. (1999). Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18, 935-941.
12. COWAN, S., HATZIIOANNOU, T., CUNNINGHAM, T., MUESING, M.A., GOTTLINGER, H.G., and BIENIASZ, P.D. (2002). Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U.S.A. 99, 11914-11919.
13. CRAVEN, R., LEURE-DUPREE, A.E., WELDON, R.A., and WILLS, J.W. (1995). Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J. Virol. 69, 4213-4227.
14. EVERETT, R.D. (2001). DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20, 7266-7273.
15. EVERETT, R.D., and MURRAY, J. (2005). ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J. Virol. 79, 5078-5089.
16. FASSATI, A., and GOFF, S.P. (1999). Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. J. Virol. 73, 8919-8925.
17. FASSATI, A., and GOFF, S.P. (2001). Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 75, 3626-3635.
18. FRANKE, E.K., YUAN, H.E., and LUBAN, J. (1994a). Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372, 359-362.
19. FRANKE, E.K., YUAN, H.E., BOSSOLT, K.L., GOFF, S.P., and LUBAN, J. (1994b). Specificity and sequence requirements for interactions between various retroviral Gag proteins. J. Virol. 68, 5300-5305.
20. GAO, F., YUE, L., WHITE, A.T., PAPPAS, P.G., BARCHUE, J., HANSON, A.P., GREENE, B.M., SHARP, P.M., SHAW, G.M., and HAHN, B.H. (1992). Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. Nature 358, 495-499.
21. GAO, F., BAILES, E., ROBERTSON, D.L., CHEN, Y., RODENBURG, C.M., MICHAEL, S.F., CUMMINS, L.B., ARTHUR, L.O., PEETERS, M., SHAW, G.M., SHARP, P.M., and HAHN, B.H. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441.
22. GOFF, S.P. (2004a). Retrovirus restriction factors. Mol. Cell 16, 849-859.
23. GOFF, S.P. (2004b). Genetic control of retrovirus susceptibility in mammalian cells. Annu. Rev. Genet. 38, 61-85.
24. HARRIS, R.S., BISHOP, K.N., SHEEHY, A.M., CRAIG, H.M., PETERSEN-MAHRT, S.K., WATT, I.N., NEUBERGER, M.S., and MALIM, M.H. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809.
25. HATZIIOANNOU, T., COWAN, S., GOFF, S.P., BIENIASZ, P.D., and TOWERS, G.J. (2003). Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22, 385-394.
26. HATZIIOANNOU, T., PEREZ-CABALLERO, D., YANG, A., COWAN, S., and BIENIASZ, P.D. (2004a). Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α. Proc. Natl. Acad. Sci. U.S.A. 101, 10774-10779.
27. HATZIIOANNOU, T., COWAN, S., VON SCHWEDLER, U.K., SUNDQUIST, W.I., and BIENIASZ, P.D. (2004b). Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78, 6005-6012.
28. HATZIIOANNOU, T., COWAN, S., and BIENIASZ, P.D. (2004c). Capsid-dependent and independent postentry restriction of primate lentivirus tropism in rodent cells. J. Virol. 78, 1006-1011.
29. HATZIIOANNOU, T., PEREZ-CABALLERO, D., COWAN, S., and BIENIASZ, P.D. (2005). Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 79, 176-183.
30. HOFMANN, W., SCHUBERT, D., LABONTE, J., MUNSON, L., GIBSON, S., SCAMMELL, J., FERRIGNO, P., and SODROSKI, J. (1999). Species-specific, postentry barriers to primate immunodeficiency virus infection. J. Virol. 73, 10020-10028.
31. IKEDA, Y., COLLINS, M.K., RADCLIFFE, P.A., MITROPHANOUS, K.A., and TAKEUCHI, Y. (2002). Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Ther. 9, 932-938.
32. IKEDA, Y., YLINEN, L., KAHAR-BADOR, M., and TOWERS, G.J. (2004). The influence of Gag on HIV-1 species specific tropism. J. Virol. 78, 11816-11822.
33. JAVANBAKHT, H., DIAZ-GRIFFERO, F., STREMLAU, M., SI, Z., and SODROSKI, J. (2005). The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5α. J. Biol. Chem. 280, 26933-26940.
34. KECKESOVA, Z., YLINEN, L.M., and TOWERS, G.J. (2004). The human and African green monkey TRIM5α genes encode Ref 1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 101, 10780-10785.
35. KOLODZIEJSKA, K.E., BURNS, A.R., MOORE, R.H., STENOIEN, D.L., and EISSA, N.T. (2005). Regulation of inducible nitric oxide synthase by aggresome formation. Proc. Natl. Acad. Sci. U.S.A. 102, 4854-4859.
36. KOOTSTRA, N.A., MUNK, C., TONNU, N., LANDAU, N.R., and VERMA, I.M. (2003). Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. U.S.A. 100, 1298-1303.
37. KOPITO, R.R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10, 524-530.
38. LI, K.S., GUAN, Y., WANG, J., SMITH, G.J., XU, K.M., DUAN, L., RAHARDJO, A.P., PUTHAVATHANA, P., BURANATHAI, C., NGUYEN, T.D., ESTOEPANGESTIE, A.T., CHAISINGH, A., AUEWARAKUL, P., LONG, H.T., HANH, N.T., WEBBY, R.J., POON, L.L., CHEN, H., SHORTRIDGE, K.F., YUEN, K.Y., WEBSTER, R.G., and PEIRIS, J.S. (2004). Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430, 209-213.
39. LI, S., HILL, C.P., SUNDQUIST, W.I., and FINCH, J.T. (2000). Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407, 409-413.
40. LI, W., ZHANG, C., SUI, J., KUHN, J.H., MOORE, M.J., LUO, S., WONG, S.K., HUANG, I.C., XU, K., VASILIEVA, N., MURAKAMI, A., HE, Y., MARASCO, W.A., GUAN, Y., CHOE, H., and FARZAN, M. (2005). Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24, 1634-1643.
41. LIN, H.K., BERGMANN, S., and PANDOLFI, P.P. (2004). Cytoplasmic PML function in TGF-β signalling. Nature 431, 205-211.
42. LUBAN, J., BOSSOLT, K.L., FRANKE, E.K., KALPANA, G.V., and GOFF, S.P. (1993). Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73, 1067-1078.
43. MANGEAT, B., TURELLI, P., CARON, G., FRIEDLI, M., PERRIN, L., and TRONO, D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103.
44. MARAIS, H., STANECKI, K., et al. (2004). AIDS Epidemic Update. (Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland). Available at URL http://www.unaids.org/wad2004/EPI_ 1204_pdf_en/Chapter0_intro_en.pdf (accessed August 2005).
45. + T cells in multiple tissues during acute SIV infection. Nature 434, 1093-1097.
46. MAUL, G.G., GULDNER, H.H., and SPIVACK, J.G. (1993). Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICPO). J. Gen. Virol. 74, 2679-2690.
47. MORTUZA, G.B., HAIRE, L.F., STEVENS, A., SMERDON, S.J., STOYE, J.P., and TAYLOR, I.A. (2004). High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431, 481-485.
48. MUNK, C., BRANDT, S.M., LUCERO, G., and LANDAU, N.R. (2002). A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. U.S.A. 99, 13843-13848.
49. NAKAYAMA, E.E., MIYOSHI, H., NAGAI, Y., and SHIODA, T. (2005). A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5α determines species-specific restriction of simian immunodeficiency virus SIV-mac infection. J. Virol. 79, 8870-8877.
50. NEGOREV, D., and MAUL, G.G. (2001). Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20, 7234-7242.
51. NISOLE, S., LYNCH, C., STOYE, J.P., and YAP, M.W. (2004). A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U.S.A. 101, 13324-13328.
52. PEREZ-CABALLERO, D., HATZIIOANNOU, T., YANG, A., COWAN, S., and BIENIASZ, P.D. (2005). Human tripartite motif 5α domains responsible for retrovirus restriction activity and specificity. J. Virol. 79, 8969-8978.
53. PERRON, M.J., STREMLAU, M., SONG, B., ULM, W., MULLIGAN, R.C., and SODROSKI, J. (2004). TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 101, 11827-11832.
54. REYMOND, A., MERONI, G., FANTOZZI, A., MERLA, G., CAIRO, S., LUZI, L., RIGANELLI, D., ZANARIA, E., MESSALI, S., CAINARCA, S., GUFFANTI, A., MINUCCI, S., PELICCI, P.C., and BALLABIO, A. (2001). The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151.
55. RYO, A., SUIZU, F., YOSHIDA, Y., PERREM, K., LIOU, Y.C., WULF, G., ROTTAPEL, R., YAMAOKA, S., and LU, K.P. (2003). Regulation of NF-κB signaling by Pin 1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12, 1413-1426.
56. SAWYER, S.L., WU, L.I., EMERMAN, M., and MALIK, H.S. (2005). Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U.S.A. 102, 2832-2837.
57. SAYAH, D.M., SOKOLSKAJA, E., BERTHOUX, L., and LUBAN, J. (2004). Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430, 569-573.
58. SCHMITZ, C., MARCHANT, D., NEIL, S.J., AUBIN, K., REUTER, S., DITTMAR, M.T., and MCKNIGHT, A. (2004). Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J. Virol. 78, 2006-2016.
59. SEBASTIAN, S., and LUBAN, J. (2005). TRIM5α selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2, 40.
60. SHARP, P.M., BAILES, E., CHAUDHURI, R.R., RODENBURG, C.M., SANTIAGO, M.O., and HAHN, B.H. (2001). The origins of acquired immune deficiency syndrome viruses: Where and when? Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 867-876.
61. SHEEHY, A.M., GADDIS, N.C., CHOI, J.D., and MALIM, M.H. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650.
62. SHEEHY, A.M., GADDIS, N.C., and MALIM, M.H. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407.
63. SINN, P.L., SAUTER, S.L., and MCCRAY, P.B. (2005). Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 12, 1089-1098.
64. SOKOLSKAJA, E., SAYAH, D.M., and LUBAN, J. (2004). Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78, 12800-12808.
65. SONG, B., JAVANBAKHT, H., PERRON, M., PARK DO, H., STREMLAU, M., and SODROSKI, J. (2005). Retrovirus restriction by TRIM5α variants from Old World and New World primates. J. Virol. 79, 3930-3937.
66. STREMLAU, M., OWENS, C.M., PERRON, M.J., KIESSLING, M., AUTISSIER, P., and SODROSKI, J. (2004). The cytoplasmic body component TRIMSa restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853.
67. STREMLAU, M., PERRON, M.J., WELIKALA, S., and SODROSKI, J. (2005). Species-specific variation in the 830.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79, 3139-3145.
68. THALI, M., BUKOVSKY, A., KONDO, E., ROSENWIRTH, B., WALSH, C.T., SODROSKI, J., and GOTTLINGER, H.G. (1994). Functional association of cyclophilin A with HIV-1 virions. Nature 372, 363-365.
69. TOWERS, G., BOCK, M., MARTIN, S., TAKEUCHI, Y., STOYE, J.P., and DANOS, O. (2000). A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. U.S.A. 97, 12295-12299.
70. TOWERS, G., COLLINS, M., and TAKEUCHI, Y. (2002). Abrogation of Ref 1 restriction in human cells. J. Virol. 76, 2548-2550.
71. TOWERS, G.J., HATZIIOANNOU, T., COWAN, S., GOFF, S.P., LUBAN, J., and BIENIASZ, P.D. (2003). Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9, 1138-1143.
72. TURELLI, P., DOUCAS, V., CRAIG, E., MANGEAT, B., KLAGES, N., EVANS, R., KALPANA, G., and TRONO, D. (2001). Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: Interference with early steps of viral replication. Mol. Cell 7, 1245-1254.
73. WEISSMAN, A.M. (2001). Themes and variations on ubiquitinylation. Nat. Rev. Mol. Cell. Biol. 2, 169-178.
74. XU, L., YANG, L., MOITRA, P.K., HASHIMOTO, K., RALLABHANDI, P., KAUL, S., MERONI, G., JENSEN, J.P., WEISSMAN, A.M., and D'ARPA, P. (2003). BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5δ. Exp. Cell Res. 288, 84-93.
75. YAP, M.W., NISOLE, S., LYNCH, C., and STOYE, J.P. (2004). Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 101, 10786-10791.
76. YAP, M.W., NISOLE, S., and STOYE, J.P. (2005). A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction. Curr. Biol. 15, 73-78.
77. YLINEN, L., KECKESOVA, Z., WILSON, S.J., RANASINGHE, S., and TOWERS, G.J. (2005). Differential restriction of HIV-2 and SIVmac by TRIM5α alleles. J. Virol. (in press).
78. ZELENT, A., GUIDEZ, F., MELNICK, A., WAXMAN, S., and LICHT, J.D. (2001). Translocations of the RARα gene in acute promyelocytic leukemia. Oncogene 20, 7186-7203.